PMX-205 is under clinical development by Teva Pharmaceutical Industries and currently in Phase I for Parkinson’s Disease. According to GlobalData, Phase I drugs for Parkinson’s Disease have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PMX-205’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PMX-205 (TDI0116) is under development for the treatment of motor neuron disease, Huntington disease, Alzheimer's disease, Parkinson's disease. It is a cyclic hexapeptide C5a receptor antagonist. C5a is a small polypeptide released from the chain of C5 during complement activation. It is administered through oral and subcutaneous route. It was also under development for the treatment of Alzheimer’s disease (AD) (Oral), Amyotrophic lateral sclerosis and inflammatory bowel disease (IBD).
Teva Pharmaceutical Industries overview
Teva Pharmaceutical Industries (Teva) discovers, develops, manufactures, and commercializes generic and specialty medicines. The company provides specialty medicines to treat disorders of the central nervous system (CNS), cancer, respiratory, dermatology, women’s health, and other disease conditions. It offers generic medicines in a range of dosage forms including capsules, tablets, injectables, liquids, inhalants, creams, and ointments. Teva also provides over-the-counter (OTC) products, besides active pharmaceutical ingredients (APIs). It also focuses on developing generic drugs. The company conducts its worldwide operations through a network of subsidiaries in regions such as North America, Europe, and International Markets. Teva is headquartered in Tel Aviv, Israel.
For a complete picture of PMX-205’s drug-specific PTSR and LoA scores, buy the report here.